3-drug therapy combining inavolisib, palbociclib, and fulvestrant doubles advanced breast cancer progression-free time in clinical trial.

A clinical trial has shown that a three-drug therapy, combining inavolisib, palbociclib, and fulvestrant, can double the time patients with advanced breast cancer live without disease progression. The study, involving 325 patients across 28 countries, revealed a delay of 15 months in disease progression compared to 7.3 months for the placebo group. While the treatment is not yet approved in the UK, it has been authorized by the U.S. FDA.

October 30, 2024
21 Articles